WO2005046689A2 - Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite - Google Patents
Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite Download PDFInfo
- Publication number
- WO2005046689A2 WO2005046689A2 PCT/FR2004/002715 FR2004002715W WO2005046689A2 WO 2005046689 A2 WO2005046689 A2 WO 2005046689A2 FR 2004002715 W FR2004002715 W FR 2004002715W WO 2005046689 A2 WO2005046689 A2 WO 2005046689A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rimonabant
- chosen
- diuretic
- cannabinoid
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the subject of the present invention is the use of a cannabinoid CB receptor antagonist compound, derived from pyrazole, for the preparation of medicaments useful in the prevention and treatment of dyslipidemias and of diseases associated with dyslipidemias and / or obesity such as, in particular, metabolic syndrome, as well as cardiovascular risks and hepatic risks.
- Dyslipidemia is defined by an increase in triglycerides, LDL-c (from English Low Density Lipoprotein Cholesterol), by a low concentration of HDL-c (from English High Density Lipoprotein Cholesterol), by the increase in the ratio total cholesterol / HDL-c, by the presence of small LDL particles.
- This dyslipidemia often present in the obese subject, is also recognized as having an atherogenic profile, that is to say which increases the risk of atheromatous disease.
- Obesity is now recognized as one of the major public health problems. Correlated with a large number of cardiovascular diseases, in particular arteriosclerosis, diabetes, hepatic diseases, in particular non-alcoholic steatohepatitis, cancers, respiratory disorders, it is associated with an increase in the mortality rate.
- the annual costs generated by the somatic complications of obesity are estimated by the World Health Organization (WHO) at one third of the world health budget.
- WHO World Health Organization
- Metabolic syndrome refers to a set of risk factors including dyslipidemia (low HDL-c level, high triglyceride level), increased abdominal girth / obesity, but also insulin resistance (hyperglycemia to fasting), and high blood pressure.
- This syndrome affects several million people worldwide, putting them at greater risk of developing diabetes with its complications of renal failure and retinopathy, or of causing cardiovascular disease such as coronary artery disease, coronary insufficiency, myocardial infarction, angina , atherosclerosis, arteriosclerosis, stroke, thrombosis, atherothrombosis or glaucoma, or a liver disease such as steatosis, non-alcoholic steatohepatitis, or non-alcoholic fatty degeneration of the liver.
- cardiovascular disease such as coronary artery disease, coronary insufficiency, myocardial infarction, angina , atherosclerosis, arteriosclerosis, stroke, thrombosis, atherothrombo
- metabolic syndrome By improving each parameter of the metabolic syndrome, particularly by preventing and treating the elements components of dyslipidemia and obesity, the prevention and treatment of metabolic syndrome in patients at risk can help reduce the onset of cardiovascular disease and type 2 diabetes or liver disease.
- the definition of metabolic syndrome is not globally unified, that given by the National Cholesterol Education Program (NCEP, USA), within the framework of a group of experts ATP III (from the English Adult Treatment Panel III) retains the criteria listed in the following table. Patients have a metabolic syndrome when they meet at least 3 of the 5 criteria indicated: increase in abdominal circumference / obesity, dyslipidemia, hypertension, hyperglycemia.
- the term “cannabinoid receptor antagonist derived from pyrazole” means a compound chosen from N-piperidino-5- (4-chlorophenyl) - 1 - (2,4-dichlorophenyl) -4-methylpyrazole-3- carboxamide, the international common name of which is rimonabant, described in European patent 656354 and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, described in European patent 1150961. Clinical studies carried out with rimonabant have shown that it acts on food intake quantitatively and qualitatively and reduces the body weight of obese patients (G. Le Fur, 2003, 35, First European Workshop on Cannabinoid Research,
- a cannabinoid CB receptor antagonist derived from pyrazole, is chosen among rimonabant and N-piperidino-5- (4-bromophenyl) - l- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, has lipid-lowering properties (in dyslipidemic subjects) which can thus contribute to decrease metabolic syndrome in patients with this syndrome, and decrease the risk of cardiovascular disease and liver disease associated with obesity and / or dyslipidemia.
- a compound cannabinoid CB receptor antagonist derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4- ethylpyrazole-3-carboxamide, can be used for the preparation of drugs useful to prevent and treat dyslipidemia and metabolic syndrome, more particularly such a compound antagonist of the CB ⁇ cannabinoid receptor can be used to treat and prevent the risks of cardiovascular diseases and liver disease associated with obesity and or dyslipidemia.
- Cardiovascular risks associated with dyslipidemia and / or obesity are understood to mean cardiovascular diseases such as: coronary artery disease, coronary insufficiency, atherosclerosis, arteriosclerosis, stroke, myocardial infarction, angina, thrombosis, atherothrombosis or glaucoma.
- cardiovascular diseases such as: coronary artery disease, coronary insufficiency, atherosclerosis, arteriosclerosis, stroke, myocardial infarction, angina, thrombosis, atherothrombosis or glaucoma.
- hepatic diseases associated with dyslipidaemia and or obesity, one understands: hepatic steatosis, non-alcoholic steatohepatitis, non-alcoholic fatty degeneration of the liver (in English: Non Alcoholic Fatty Liver Disease).
- compositions according to the present invention contain an effective dose of a cannabinoid CBj receptor antagonist compound, derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4 - dichlorophenyl) -4-ethylpyrazole-3-carboxamide, as well as at least one pharmaceutically acceptable excipient.
- a cannabinoid CBj receptor antagonist compound derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4 - dichlorophenyl) -4-ethylpyrazole-3-carboxamide, as well as at least one pharmaceutically acceptable excipient.
- Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
- the active principle can be administered in unit administration form, in mixture with conventional pharmaceutical excipients, to animals and humans for the prevention or treatment of disorders or diseases above.
- suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular, intranasal administration forms , by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- Forms for oral administration such as capsules or tablets are preferred. More particularly, capsules or tablets containing rimonabant are preferred at a dose of between 5 and 50 mg, more particularly doses of 5 and 20 mg.
- a cannabinoid receptor antagonist derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4- ethylpyrazole-3-carboxamide
- another active ingredient chosen from one of the following therapeutic classes: - an angiotensin II receptor antagonist AT], alone or combined with a diuretic; - a converting enzyme inhibitor, alone or combined with a diuretic or a calcium antagonist; - a calcium antagonist; - a beta-blocker alone or combined with a diuretic or a calcium antagonist; - an antihyperlipaptant or an antihypercholestérolaptant; - an anti-diabetic; - another anti-obesity agent.
- the present invention also relates to pharmaceutical compositions containing in association a cannabinoid CBj receptor antagonist, derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2, 4-dichlorophenyl) -4-ethylpyrazole-3-carboxamide, and another active ingredient chosen from one of the following therapeutic classes: - an angiotensin II AT ⁇ receptor antagonist, alone or in combination with a diuretic or a calcium antagonist; - an ACE inhibitor, alone or in combination with a diuretic; - a calcium antagonist; - a beta-blocker alone or combined with a diuretic or a calcium antagonist; - an antihyperlipaptant or an antihypercholestérolaptant; - an anti-diabetic; - another anti-obesity agent.
- a cannabinoid CBj receptor antagonist derived from pyrazole, chosen from rimona
- angiotensin II ATi receptor antagonist is meant a compound such as candesartan cilexitil, eprosartan, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan, each of these compounds being able to be itself associated with a diuretic such as l hydrochlorothiazide.
- converting enzyme inhibitor is meant a compound such as alacépril, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trofenopril of these compounds which can itself be combined with a diuretic such as hydrochlorothiazide or indapamide or with a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
- a diuretic such as hydrochlorothiazide or indapamide
- a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
- calcium antagonist means a compound such as amlodipine, aranidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine hydrochloride ethanol, fasudil, feludipipine, lacidipine, lercanidipine hydrochloride, manidipine nipidipine nidipine, nidipine hydrochloride nisoldipine, nitrendipine, terodiline, verapamil.
- beta-blocker is meant a compound such as acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, butofilolol, carololololololololololololololol , indenolol, labetalol, levobunolol, levomoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolo
- the present invention has for subject a pharmaceutical composition containing in combination rimonabant, atorvastatin or pravastatin, or preferably rimonabant and simvastatin.
- antidiabetic means a compound belonging to one of the following classes: sulfonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinedione, metiglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide , glimepiride, glipizide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone,
- anti-obesity agent a compound such as amfepramone, benfluorex, benzphetamine, indanorex, mazindole, mefenorex, methamphetamine, D-norpseudoephedrine or another antagonist of CB ⁇ cannabinoid receptors.
- the subject of the present invention is a pharmaceutical composition containing in combination rimonabant and an angiotensin II AT1 receptor antagonist, in particular irbesartan, losartan or valsartan.
- the present invention relates to a pharmaceutical composition containing in association rimonabant and irbesartan or N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) -4-ethyl ⁇ yrazole-3 -carboxamide and irbesartan, as well as a pharmaceutical composition containing in combination rimonabant, irbesartan and hydrochlorothiazide or N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) - 4-ethylpyrazole-3-carboxamide, irbesartan and hydrochlorothiazide.
- the present invention relates to a pharmaceutical composition containing in combination rimonabant and simvastatin.
- the cannabinoid receptor antagonist derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) - 1 - (2,4-dichlorophenyl) -4 -ethylpyrazole-3 -carboxamide, and the other associated active ingredient can be administered simultaneously, separately or spread over time.
- “separate use” is meant the administration, at the same time, of the two compounds of the composition according to the invention, each included in a separate pharmaceutical form.
- use spread over time means the successive administration of the first compound of the composition according to the invention, included in a pharmaceutical form, then of the second compound of the composition according to the invention, included in a form separate pharmaceutical.
- the period of time between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention does not exceed generally not 24 hours, it may be higher if one or the other of the compounds is presented in a pharmaceutical formulation allowing, for example, weekly administration.
- the pharmaceutical forms comprising either only one of the constituent compounds of the composition according to the invention or the combination of the two compounds, or if necessary of three compounds, which can be used in the different types of uses described below.
- the invention therefore also relates to a kit containing a cannabinoid CB i receptor antagonist, derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) - 4-ethylpyrazole-3-carboxamide, and another active principle or, where appropriate, two associated active principles in which said cannabinoid CB receptor antagonist, derivative of pyrazole, and said active principle or, where appropriate, two active principles associated are in separate compartments and in similar or different packaging, and are intended to be administered simultaneously, separately or spread over time.
- a cannabinoid CB i receptor antagonist derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4-bromophenyl) -l- (2,4-dichlorophenyl) - 4-ethylpyrazole-3-carboxamide
- mice with established obesity The effect of long-term (2 months) treatment with rimonabant was studied in mice with established obesity.
- the study was carried out in mice receiving either a normal diet or a fatty diet. Obesity developed in mice receiving a fatty diet and stabilized after 5 months.
- the mice were then divided into 3 groups:, group 1: maintenance of the fatty diet and oral treatment for 2 months with rimonabant at 10 mg / kg / day, in water with 0.1% Tween 80 (vehicle); group 2: maintenance of the fatty diet and administration of the vehicle (water + 0.1% of Tween 80); group 3: return to a normal diet and administration of the vehicle (water + 0.1% Tween 80); group 4 consists of mice receiving from the start a normal diet and the vehicle.
- group 1 maintenance of the fatty diet and oral treatment for 2 months with rimonabant at 10 mg / kg / day, in water with 0.1% Tween 80 (vehicle);
- group 2 maintenance of the fatty
- mice After 5 months of a fatty diet, the mice showed a 46% weight gain and a marked increase in serum leptin, insulin, glucose and total cholesterol levels.
- the levels of HDLc (from English: high density lipoprotein cholesterol) and LDLc (from English: low density lipid cholesterol) were measured for these obese mice and an increase in these levels was observed, accompanied by a decrease in HDLc / LDLc ratio.
- the weight of group 1 mice decreased by 34.5 + 0.8 g, that is to say in the same proportions as that of group 3 mice brought back to a normal diet. (33.7 + 0.6 g).
- mice showed a reduction in serum leptin, insulin and glucose levels; in the same way, these levels were reduced for the mice of group 3.
- the data measured during the assays of the triglycerides and the lipoproteins of cholesterol are reported in the tables below:
- n number of animals. From Tables 2 and 3, it can be seen that treatment with rimonabant, as administered to animals in group 1, corrects the hypertriglyceridemia observed in animals fed a fatty diet (group 2). According to Tables 2 and 3, it can be seen that treatment with rimonabant makes it possible to lower the total cholesterol level, but not to normalize it; this same treatment normalizes the LDLc level with the consequence of increasing the HDLc / LDLc ratio.
- a clinical trial was carried out for 4 weeks on 287 obese patients whose body mass index (in English BMI: body mass index) was between 30 and 40. After receiving placebo for 2 weeks, the patients were randomized to receive doses of 5, 10 or 20 mg / day of rimonabant or the placebo. A follow-up visit was made 4 weeks after the end of treatment. During the study period, patients were asked to follow a low-calorie diet (deficit of 500 kcal / day). The results observed at the end of the treatment are reported in the following table:
- Adiponectin reflects the state of insulin resistance: the change in its rate is inversely proportional to that of insulin resistance.
- the increase in the rate of adiponectin indicates the decrease in the rate of insulin resistance.
- 60.2% of patients cease to display the characteristics of the metabolic syndrome, while the proportion is 40.4% in the placebo group (p ⁇ 0.001).
- the placebo group being subjected to the same low-calorie diet as the treated group, it appears that rimonabant has a specific effect on the reduction of the metabolic syndrome.
- EXAMPLE 4 Effect of rimonabant on steatosis and steatohepatitis in obese rats.
- the effect of rimonabant on steatosis and steatohepatitis has been studied in obese Zucker fa / fa rats.
- Obese Zucker fa / fa rats, whose functionally defective leptin receptors, show obesity associated with hyperleptinemia, hyperinsulinemia, dyslipidemia and exhibit steatohepatitis.
- 3 groups are made up: - Group of thin rats / vehicle: thin Zucker rats treated with the vehicle (water and 0.1% Tween 80). - Obese rats / vehicle group: Zucker obese fa / fa rats treated by the vehicle (water and 0.1% Tween 80). - Obese rats / rimonabant group: Zucker obese fa / fa rats treated orally for 2 months with rimonabant at 30 mg / kg / day, in the vehicle (water and 0.1% Tween 80). After 2 months of treatment, the body weight and the weight of the liver are measured for each rat and a histopathological analysis of the fatty load of the livers is carried out.
- liver / body weight ratio is 41% higher in the group of obese / vehicle rats compared to the group of thin rats / vehicle.
- the treatment of obese fa / fa rats with rimonabant reduces by 80% the increase in the liver / body weight ratio observed in the rats of the obese / vehicle group, to reach a ratio of a value comparable to that observed in the group of thin rats / vehicle (Table 5).
- EXAMPLE 5 Action of rimonabant and irbesartan on plasma lipid levels in obese rats.
- the effect of rimonabant alone or in combination with irbesartan was studied in the obese Zucker fa / fa rat.
- group 1 thin Zucker rats treated with the vehicle
- group 2 obese Zucker rats fa / fa treated with the vehicle
- group 3 obese Zucker rats fa / fa treated with the rimonabant at 1 mg / kg / day
- group 4 obese Zucker fa / fa rats treated with rimonabant 3 mg / kg / day per os
- group 5 obese Zucker fa / fa rats treated with irbesartan 3 mg / kg / day per os
- group 6 obese Zucker fa / fa rats treated with rimonabant at 1 mg / kg / day per os and irbesartan 3 mg / kg / day per os
- group 7 obese Zucker fa / fa rats treated with rimonabant rimonabant at 3 mg / kg / day orally and irbesartan 3 mg / kg / day or
- rimonabant + irbesartan significantly reduces the plasma cholesterol and triglyceride levels in obese Zucker fa / fa rats.
- the administration of the 2 associated compounds improves the HDLc / LDLc ratio for the treated animals.
- EXAMPLE 6 Pharmaceutical composition.
- rimonabant is formulated in compositions which are harmless and which are re-arried by wet ranulation.
- Povidone is defined in the European Pharmacopoeia as follows: poly (1- (2-oxo-1-pyrrolidinyl) ethylene) and is made up of linear polymers of 1-vinylpyrrolidin-2-one. The tablets are preferably coated using an appropriate excipient.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ547375A NZ547375A (en) | 2003-10-24 | 2004-10-22 | Use of rimonabant and an angiotensin II AT1 receptor antagonist for preparing medicaments for the prevention and the treatment of dyslipidemia and/or obesity |
AU2004289078A AU2004289078A1 (en) | 2003-10-24 | 2004-10-22 | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
CA002543582A CA2543582A1 (fr) | 2003-10-24 | 2004-10-22 | Utilisation d'un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite |
YUP-2006/0344A RS20060344A (en) | 2003-10-24 | 2004-10-22 | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
MEP-106/08A MEP10608A (en) | 2003-10-24 | 2004-10-22 | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
BRPI0415538-6A BRPI0415538A (pt) | 2003-10-24 | 2004-10-22 | utilização de um derivado do pirazol para o preparo de medicamento úteis na prevenção e no tratamento das dislipidemias e das doenças associadas às dislipidemias e/ou à obesidade |
JP2006536128A JP2007509113A (ja) | 2003-10-24 | 2004-10-22 | 異脂肪血症並びに異脂肪血症および/または肥満症に関連する疾患の予防および治療において有用である医用製品の調製へのピラゾール誘導体の使用 |
EP04805278A EP1680117A2 (fr) | 2003-10-24 | 2004-10-22 | Utilisation d'un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite |
IL175103A IL175103A0 (en) | 2003-10-24 | 2006-04-23 | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
US11/410,226 US20070072907A1 (en) | 2003-10-24 | 2006-04-24 | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity |
NO20062369A NO20062369L (no) | 2003-10-24 | 2006-05-24 | Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme |
US12/463,652 US20090215755A1 (en) | 2003-10-24 | 2009-05-11 | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312553 | 2003-10-24 | ||
FR0312553A FR2861300B1 (fr) | 2003-10-24 | 2003-10-24 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
FR0314763A FR2861301B1 (fr) | 2003-10-24 | 2003-12-15 | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0314763 | 2003-12-15 | ||
FR0401193A FR2861302A1 (fr) | 2003-10-24 | 2004-02-05 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0401193 | 2004-02-05 | ||
FR0403252 | 2004-03-26 | ||
FR0403252A FR2861303A1 (fr) | 2003-10-24 | 2004-03-26 | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/410,226 Continuation US20070072907A1 (en) | 2003-10-24 | 2006-04-24 | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005046689A2 true WO2005046689A2 (fr) | 2005-05-26 |
WO2005046689A3 WO2005046689A3 (fr) | 2005-10-13 |
Family
ID=34426973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/002715 WO2005046689A2 (fr) | 2003-10-24 | 2004-10-22 | Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite |
Country Status (18)
Country | Link |
---|---|
US (2) | US20070072907A1 (fr) |
EP (1) | EP1680117A2 (fr) |
JP (1) | JP2007509113A (fr) |
KR (1) | KR20060100443A (fr) |
AR (3) | AR047764A1 (fr) |
AU (1) | AU2004289078A1 (fr) |
BR (1) | BRPI0415538A (fr) |
CA (1) | CA2543582A1 (fr) |
FR (1) | FR2861303A1 (fr) |
IL (1) | IL175103A0 (fr) |
MA (1) | MA28105A1 (fr) |
ME (1) | MEP10608A (fr) |
NZ (1) | NZ547375A (fr) |
RS (1) | RS20060344A (fr) |
RU (1) | RU2357731C2 (fr) |
SG (1) | SG149078A1 (fr) |
TW (1) | TWI286935B (fr) |
WO (1) | WO2005046689A2 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005084652A2 (fr) * | 2004-03-09 | 2005-09-15 | Inserm | Utilisation d'antagonistes du recepteur cb1 pour preparer une composition utile pour le traitement des maladies hepatiques |
EP1745781A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin |
EP1745782A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de pyrazolines substituées pour la fabrication d' un médicament pour le traitement de la syndrome métabolique |
WO2007009694A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr.Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour l'elaboration de medicaments destines au traitement du syndrome metabolique |
WO2007009698A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Association d'une statine et d'un antagoniste pyrazolinique des cannabinoides |
ES2324139A1 (es) * | 2007-01-16 | 2009-07-30 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas. |
ES2326857A1 (es) * | 2005-07-15 | 2009-10-20 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidos del sindrome metabolico. |
WO2010128191A1 (fr) * | 2009-05-04 | 2010-11-11 | Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Fundación Imabis) | Dérivés de pirazol bivalents utilisés en tant qu'inhibiteurs de l'ingesta |
US9370504B2 (en) | 2008-08-04 | 2016-06-21 | Snu R&Db Foundation | Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1985295A1 (fr) | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibiteurs sélectifs de l'expression du récepteur CB2 et/ou activité pour le traitement de l'obésité et troubles liés à l'obésité |
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
RU2568896C2 (ru) * | 2013-07-31 | 2015-11-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему |
US10835501B2 (en) * | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758723A1 (fr) * | 1997-01-28 | 1998-07-31 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
WO2000046209A1 (fr) * | 1999-02-01 | 2000-08-10 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
WO2001024798A1 (fr) * | 1999-10-01 | 2001-04-12 | Sanofi-Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoïdes centraux pour la preparation de medicaments |
WO2002028346A2 (fr) * | 2000-10-04 | 2002-04-11 | Aventis Pharma S.A. | Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite |
WO2003077847A2 (fr) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Amides substitues |
WO2003087037A1 (fr) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Arylamides substituee |
WO2004004655A2 (fr) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Derives heterocycliques substitues utiles comme agents antidiabetique et anti-obesite et procede correspondant |
WO2004009015A2 (fr) * | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Polytherapie pour le traitement de l'obesite |
WO2004012671A2 (fr) * | 2002-08-02 | 2004-02-12 | Merck & Co., Inc. | Derives furo [2,3-b] pyridine substitues |
WO2004031175A2 (fr) * | 2002-09-30 | 2004-04-15 | Banyu Pharmaceutical Co., Ltd. | Derives de -2-oxodihydropyridine a substitution n |
WO2004034968A2 (fr) * | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Polythérapie pour contrôler l'appétit |
WO2004096132A2 (fr) * | 2003-04-25 | 2004-11-11 | Pharmacia Corporation | Combinaison d'un antagoniste du recepteur d'aldosterone et d'un agent anti-obesite |
WO2004110375A2 (fr) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie permettant de traiter le diabete |
WO2004110368A2 (fr) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie pour le traitement de l'hypertension |
WO2005000217A2 (fr) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Polytherapie permettant de traiter la dyslipidemie |
WO2005020992A1 (fr) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb1 |
WO2005030758A1 (fr) * | 2003-09-25 | 2005-04-07 | Bristol-Myers Squibb Company | Derives de pyrimidine et de pyridine utiles comme inhibiteurs de la hmg-coa reductase, et methode de preparation desdits derives |
WO2005039579A1 (fr) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Traitement de l'obesite combinant des antagonistes de cb1 selectifs et des inhibiteurs de lipase |
EP1574211A1 (fr) * | 2004-03-09 | 2005-09-14 | Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
WO2005094305A2 (fr) * | 2004-03-31 | 2005-10-13 | Neurogen Corporation | Polytherapie pour la gestion du poids |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
DE60215960T2 (de) * | 2001-09-21 | 2007-03-01 | Solvay Pharmaceuticals B.V. | Neue 4,5-dihydro-1h-pyrazol-derivate mit cb1-antagonistischer wirkung |
US6864268B2 (en) * | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
US20050281868A1 (en) * | 2004-06-21 | 2005-12-22 | Fairfield Clinical Trials, Llc | Transdermal delivery system for statin combination therapy |
-
2004
- 2004-03-26 FR FR0403252A patent/FR2861303A1/fr not_active Withdrawn
- 2004-10-21 AR ARP040103811A patent/AR047764A1/es not_active Application Discontinuation
- 2004-10-22 SG SG200809686-9A patent/SG149078A1/en unknown
- 2004-10-22 RS YUP-2006/0344A patent/RS20060344A/sr unknown
- 2004-10-22 RU RU2006117790/15A patent/RU2357731C2/ru not_active IP Right Cessation
- 2004-10-22 KR KR1020067009975A patent/KR20060100443A/ko not_active Application Discontinuation
- 2004-10-22 AU AU2004289078A patent/AU2004289078A1/en not_active Abandoned
- 2004-10-22 CA CA002543582A patent/CA2543582A1/fr not_active Abandoned
- 2004-10-22 WO PCT/FR2004/002715 patent/WO2005046689A2/fr active Application Filing
- 2004-10-22 JP JP2006536128A patent/JP2007509113A/ja not_active Withdrawn
- 2004-10-22 TW TW093132275A patent/TWI286935B/zh not_active IP Right Cessation
- 2004-10-22 NZ NZ547375A patent/NZ547375A/en unknown
- 2004-10-22 BR BRPI0415538-6A patent/BRPI0415538A/pt not_active IP Right Cessation
- 2004-10-22 ME MEP-106/08A patent/MEP10608A/xx unknown
- 2004-10-22 EP EP04805278A patent/EP1680117A2/fr not_active Withdrawn
-
2006
- 2006-04-23 IL IL175103A patent/IL175103A0/en unknown
- 2006-04-24 US US11/410,226 patent/US20070072907A1/en not_active Abandoned
- 2006-04-24 MA MA28959A patent/MA28105A1/fr unknown
-
2007
- 2007-11-05 AR ARP070104905A patent/AR063551A2/es unknown
- 2007-11-05 AR ARP070104904A patent/AR063550A2/es unknown
-
2009
- 2009-05-11 US US12/463,652 patent/US20090215755A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758723A1 (fr) * | 1997-01-28 | 1998-07-31 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
WO2000046209A1 (fr) * | 1999-02-01 | 2000-08-10 | Sanofi-Synthelabo | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
WO2001024798A1 (fr) * | 1999-10-01 | 2001-04-12 | Sanofi-Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoïdes centraux pour la preparation de medicaments |
WO2002028346A2 (fr) * | 2000-10-04 | 2002-04-11 | Aventis Pharma S.A. | Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite |
WO2003077847A2 (fr) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Amides substitues |
WO2003087037A1 (fr) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Arylamides substituee |
WO2004004655A2 (fr) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Derives heterocycliques substitues utiles comme agents antidiabetique et anti-obesite et procede correspondant |
WO2004009015A2 (fr) * | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Polytherapie pour le traitement de l'obesite |
WO2004012671A2 (fr) * | 2002-08-02 | 2004-02-12 | Merck & Co., Inc. | Derives furo [2,3-b] pyridine substitues |
WO2004034968A2 (fr) * | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Polythérapie pour contrôler l'appétit |
WO2004031175A2 (fr) * | 2002-09-30 | 2004-04-15 | Banyu Pharmaceutical Co., Ltd. | Derives de -2-oxodihydropyridine a substitution n |
WO2004096132A2 (fr) * | 2003-04-25 | 2004-11-11 | Pharmacia Corporation | Combinaison d'un antagoniste du recepteur d'aldosterone et d'un agent anti-obesite |
WO2004110375A2 (fr) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie permettant de traiter le diabete |
WO2004110368A2 (fr) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie pour le traitement de l'hypertension |
WO2005000217A2 (fr) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Polytherapie permettant de traiter la dyslipidemie |
WO2005020992A1 (fr) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb1 |
WO2005030758A1 (fr) * | 2003-09-25 | 2005-04-07 | Bristol-Myers Squibb Company | Derives de pyrimidine et de pyridine utiles comme inhibiteurs de la hmg-coa reductase, et methode de preparation desdits derives |
WO2005039579A1 (fr) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Traitement de l'obesite combinant des antagonistes de cb1 selectifs et des inhibiteurs de lipase |
EP1574211A1 (fr) * | 2004-03-09 | 2005-09-14 | Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
WO2005094305A2 (fr) * | 2004-03-31 | 2005-10-13 | Neurogen Corporation | Polytherapie pour la gestion du poids |
Non-Patent Citations (8)
Title |
---|
"KARDIOVASKULAERES RISIKOMANAGEMENT MIT RIMONABANT GEGEN UEBERGEWICHT UND RAUCHEN CARDIOVASCULAR RISK MANAGEMENT: RIMONABANT AGAINST OVERWEIGHT AND SMOKING" DEUTSCHE APOTHEKER ZEITUNG, DEUTSCHER APOTHEKER ZEITUNG, STUTTGART, DE, vol. 144, no. 12, 18 mars 2004 (2004-03-18), pages 48-50, XP008031411 ISSN: 0011-9857 * |
ABATE NICOLA: "Obesity as a risk factor for cardiovascular disease" AMERICAN JOURNAL OF MEDICINE, vol. 107, no. 2 PART A, 23 août 1999 (1999-08-23), pages 12S-13S, XP002329573 ISSN: 0002-9343 * |
BATKAI S ET AL: "ENDOCANNABINOIDS ACTING AT VASCULAR CB1 RECEPTORS MEDIATE THE VASODILATED STATE IN ADVANCED LIVER CIRRHOSIS" NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 7, juillet 2001 (2001-07), pages 827-832, XP001120431 ISSN: 1078-8956 * |
BEERS M.H., BERKOW M.D.: "The Merck Manual of Diagnosis and Therapy, seventeenth edition" 1999, MERCK RESEARCH LABORATORIES , WHITEHOUSE STATION, N.J. , XP002329574 page 58 - page 62 * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2005, LANE, EDWARD M.: "Transdermal delivery system for statin combination therapy" XP002366941 extrait de STN Database accession no. 2005:1335082 -& US 2005/281868 A1 (LANE, EDWARD M.) 22 décembre 2005 (2005-12-22) * |
GABBAY E ET AL: "TREATMENT WITH AN ENDOCANNABINOID ANTAGONIST IMPROVES NEUROLOGIC FUNCTION AND SURVIVAL IN AN ANIMAL MODEL OF FULMINANT HEPATIC FAILURE" HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 34, no. 4, SUPPL 1, 24 octobre 2003 (2003-10-24), page 541A, XP008033135 ISSN: 0270-9139 * |
See also references of EP1680117A2 * |
XP002283450 Extrait de l'Internet: URL:http://www.clinicaltrials.gov/ct/show/NCT00029835?order=1> [extrait le 2002-11] * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2305220A3 (fr) * | 2004-03-09 | 2011-05-18 | Institut National de la Santé et de la Recherche Médicale - Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
WO2005084652A3 (fr) * | 2004-03-09 | 2005-12-08 | Inst Nat Sante Rech Med | Utilisation d'antagonistes du recepteur cb1 pour preparer une composition utile pour le traitement des maladies hepatiques |
WO2005084652A2 (fr) * | 2004-03-09 | 2005-09-15 | Inserm | Utilisation d'antagonistes du recepteur cb1 pour preparer une composition utile pour le traitement des maladies hepatiques |
US8604060B2 (en) | 2004-03-09 | 2013-12-10 | Inserm | Use of antagonists of the CBI receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
US8236763B2 (en) | 2004-03-09 | 2012-08-07 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
EP1745781A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin |
EP1745782A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de pyrazolines substituées pour la fabrication d' un médicament pour le traitement de la syndrome métabolique |
WO2007009694A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr.Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour l'elaboration de medicaments destines au traitement du syndrome metabolique |
WO2007009698A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Association d'une statine et d'un antagoniste pyrazolinique des cannabinoides |
ES2325722A1 (es) * | 2005-07-15 | 2009-09-14 | Laboratorios Del Dr.Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para la preparacion de medicamentos para el tratamiento del sindrome metabolico. |
ES2326857A1 (es) * | 2005-07-15 | 2009-10-20 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidos del sindrome metabolico. |
ES2324139A1 (es) * | 2007-01-16 | 2009-07-30 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas. |
US9370504B2 (en) | 2008-08-04 | 2016-06-21 | Snu R&Db Foundation | Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of LXR-α |
ES2349838A1 (es) * | 2009-05-04 | 2011-01-11 | Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im | Derivados de pirazol bivalentes como inhibidores de ingesta. |
WO2010128191A1 (fr) * | 2009-05-04 | 2010-11-11 | Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Fundación Imabis) | Dérivés de pirazol bivalents utilisés en tant qu'inhibiteurs de l'ingesta |
Also Published As
Publication number | Publication date |
---|---|
EP1680117A2 (fr) | 2006-07-19 |
AU2004289078A1 (en) | 2005-05-26 |
US20090215755A1 (en) | 2009-08-27 |
TW200526216A (en) | 2005-08-16 |
US20070072907A1 (en) | 2007-03-29 |
RU2006117790A (ru) | 2007-12-10 |
TWI286935B (en) | 2007-09-21 |
BRPI0415538A (pt) | 2006-12-26 |
IL175103A0 (en) | 2008-04-13 |
KR20060100443A (ko) | 2006-09-20 |
NZ547375A (en) | 2009-10-30 |
RS20060344A (en) | 2008-08-07 |
SG149078A1 (en) | 2009-01-29 |
FR2861303A1 (fr) | 2005-04-29 |
RU2357731C2 (ru) | 2009-06-10 |
WO2005046689A3 (fr) | 2005-10-13 |
AR047764A1 (es) | 2006-02-22 |
MA28105A1 (fr) | 2006-08-01 |
AR063550A2 (es) | 2009-01-28 |
JP2007509113A (ja) | 2007-04-12 |
MEP10608A (en) | 2010-06-10 |
AR063551A2 (es) | 2009-01-28 |
CA2543582A1 (fr) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070072907A1 (en) | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity | |
EP2545920A1 (fr) | Thérapie pour complications du diabète | |
EP1998768A2 (fr) | Antagonistes du crf1 pour la préparation de médicaments pour le traitement du syndrome métabolique et/ou de l'obesité et/ou de la dyslipoproteinemie | |
FR2639226A1 (fr) | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs | |
EP0429360B1 (fr) | Inhibition du syndrome d'abstinence | |
FR2861301A1 (fr) | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. | |
US7622488B2 (en) | Use of a pyrazole derivative for preparing medicines useful for treating renal diseases | |
FR2861302A1 (fr) | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. | |
Miyata et al. | From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy | |
EP0828486A1 (fr) | Utilisation de derives de pyrrolidine au traitement de l'alcoolisme | |
FR2882262A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
WO2006087481A1 (fr) | Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 | |
FR2882261A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 | |
MXPA06004554A (en) | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity | |
CN1893946A (zh) | 吡唑衍生物在制备用于预防和治疗异常脂血症以及与异常脂血症和/或肥胖有关的疾病的药物中的应用 | |
FR2882264A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 | |
WO1996028161A1 (fr) | Utilisation des derives de 2-[4-(azolylbutyl)-piperazinyl-methyl]-benzimidazole pour le traitement de la conjonctivite allergique | |
Vicente et al. | Cerebrocrast as a neuroprotective, anti-diabetic and mitochondrial bioenergetic effector: A putative mechanism of action | |
JP2007509110A (ja) | Cb1拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体とリパーゼ阻害剤とを含む組み合わせでの肥満症治療 | |
EP2131842A2 (fr) | Utilisation d'un compose antagoniste des recepteurs nk-2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles | |
WO1997033582A1 (fr) | Compositions d'antagonistes de site polyamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480034732.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 06038072 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 175103 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543582 Country of ref document: CA Ref document number: 12006500821 Country of ref document: PH Ref document number: PA/a/2006/004554 Country of ref document: MX Ref document number: 2006536128 Country of ref document: JP Ref document number: 11410226 Country of ref document: US Ref document number: 1404/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004805278 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2006000237 Country of ref document: DZ |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 547375 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067009975 Country of ref document: KR Ref document number: P-2006/0344 Country of ref document: YU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/04178 Country of ref document: ZA Ref document number: 200604178 Country of ref document: ZA Ref document number: 2006117790 Country of ref document: RU Ref document number: 2004289078 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004289078 Country of ref document: AU Date of ref document: 20041022 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004289078 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004805278 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067009975 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0415538 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11410226 Country of ref document: US |